Investigational drug · Phase 3
MRG004A
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Pancreatic Cancer.
Phase 3Last checked: Nov 19, 2026Latest source record: May 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "MRG004A"
First trial start
2027
Jan 2027
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "MRG004A", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Pancreatic Cancer
Approved drugs for the same conditions: Pancreatic cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "MRG004A" as an intervention, largest first.
- A Study Comparing MRG004A Plus Best Supportive Care Versus Placebo and Best Supportive Care in the Treatment of Patients With Advanced Pancreatic CancerPivotal-lookingNot yet recruiting
Lepu Biopharma Co., Ltd.Industry
NCT07138846 · 231 participants (planned) · Start Jan 2027 · Primary completion Jun 2027
Drug: MRG004A plus best supportive care; Placebo plus best supportive care · For: Advanced Pancreatic Cancer
Sites: Shanghai, China
- A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid TumorsCompleted
Lepu Biopharma Co., Ltd.Industry
NCT04843709 · 39 participants · Start Jul 26, 2021 · Primary completion Mar 20, 2024
Drug: MRG004A · For: Advanced or Metastatic Solid Tumors
Sites: Orange, California; New York, New York; Canton, Ohio · 9 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Tissue factor promotes TREX1 protein stability to evade cGAS-STING innate immune response in pancreatic ductal adenocarcinoma.
Xue Y, Wang Y, Ren Z, et al. · Oncogene 2025
- Tissue factor overexpression in triple-negative breast cancer promotes immune evasion by impeding T-cell infiltration and effector function.
Ren Z, Xue Y, Liu L, et al. · Cancer Lett 2023
- Generation of DAR1 Antibody-Drug Conjugates for Ultrapotent Payloads Using Tailored GlycoConnect Technology.
de Bever L, Popal S, van Schaik J, et al. · Bioconjug Chem 2023
Also in development for Advanced Pancreatic Cancer
- LM-108Phase 36 trials
LaNova Medicines Limited · Advanced Solid Tumor, Advanced Pancreatic Cancer, Locally Advanced or Metastatic GC and GCJ Adenocarcinoma
- BotensilimabAGEN1181, 8541APhase 24 trials
Agenus Inc. · Metastatic Colorectal Cancer, Refractory Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC), Untreated
- GKL-006iNKT cellsPhase 22 trials
Beijing Gene Key Life Technology Co., Ltd · Advanced Pancreatic Cancer, Ductal Adenocarcinoma of Pancreas, Hepatocellular Carcinoma (HCC)
- NLM-001Phase 22 trials
Nelum Corp · Untreated, Advanced Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma
- BalstililmabPhase 21 trial
Nelum Corp · Untreated, Advanced Pancreatic Cancer
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.